Effects of venetoclax, a BCL2 inhibitor, in systemic chronic active Epstein-Barr virus disease

Abstract Systemic chronic active Epstein-Barr virus disease (sCAEBV) is a chemotherapy-resistant, EBV-positive T- or NK-cell lymphoproliferative disorder characterized by persistent systemic inflammation driven by the activation of EBV-infected cells. In this study, we explored BCL2, an anti-apoptot...

Full description

Bibliographic Details
Published in:	Scientific Reports
Main Authors:	Ayaka Ohashi, Miwako Nishio, Mayumi Yoshimori, Kaoru Koike, Morito Kurata, Hayato Tamai, Ken-Ichi Imadome, Ayako Arai
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-05-01
Subjects:	Venetoclax BCL2 Systemic chronic active Epstein-Barr virus disease sCAEBV EBV
Online Access:	https://doi.org/10.1038/s41598-025-03719-9

Similar Items

The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection
by: Ayaka Ohashi, et al.
Published: (2022-04-01)

Plasma interferon-γ concentration: a potential biomarker of disease activity of systemic chronic active Epstein-Barr virus infection
by: Yu Uemura, et al.
Published: (2022-09-01)

Clinical significance of anti-Epstein–Barr virus antibodies in systemic chronic active Epstein–Barr virus disease
by: Miwako Nishio, et al.
Published: (2024-01-01)

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
by: Joel D. Leverson, et al.
Published: (2018-10-01)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
by: Xi Xu, et al.
Published: (2023-10-01)

Bcl-2 inhibition in the treatment of hematologic malignancies
by: John X. Wei, et al.
Published: (2023-12-01)

Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma
by: Seiichi Okabe, et al.
Published: (2025-06-01)

CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements
by: Delin Yuan, et al.
Published: (2021-03-01)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
by: Mike-Andrew Westhoff, et al.
Published: (2022-01-01)

Progress in understanding the mechanisms of resistance to BCL-2 inhibitors
by: Yilan Xu, et al.
Published: (2022-05-01)

Mechanisms of venetoclax resistance and solutions
by: Jiachen Liu, et al.
Published: (2022-10-01)

Correlation between Bcl-2 Expression and the Efficacy of Bcl-2 Inhibitors in Patients with Myelodysplastic Syndromes
by: WU Jiafei, WANG Jun, WANG Yijing, ZHENG Boyue, WANG Yu, JIANG Chuanyan, DONG Dandan, LI Hui
Published: (2024-06-01)

Targeting BCL2 in Waldenström macroglobulinemia: from biology to treatment management
by: Eleni Kalafati, et al.
Published: (2025-04-01)

Chronic active Epstein–Barr virus and hydroa vacciniforme‐like lymphoproliferative disorder in a pediatric patient complicated by fatal ruptured cerebral artery aneurysm
by: Troy Yi, et al.
Published: (2023-06-01)

A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
by: Tianming Zhao, et al.
Published: (2023-01-01)

Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
by: Xinyi Jian, et al.
Published: (2024-06-01)

Sintilimab treatment for chronic active Epstein–Barr virus infection and Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children
by: Ruyue Chen, et al.
Published: (2023-09-01)

Review of BCL2 inhibitors for the treatment of Waldenström’s macroglobulinaemia and non-IgM lymphoplasmacytic lymphoma
by: Oliver Tomkins, et al.
Published: (2024-11-01)

Targeting BCL-2 family proteins using BH3 mimetic drugs for cancer therapy: A systematic review of randomized clinical trials
by: Fatimah Alharbi, et al.
Published: (2024-12-01)

Population Pharmacokinetic Models of Venetoclax in Hematologic Malignancies: A Systematic Review
by: Zhao Y, et al.
Published: (2024-05-01)

Venetoclax-Related Neutropenia in Leukemic Patients: A Comprehensive Review of the Underlying Causes, Risk Factors, and Management
by: Laura Giuseppina Di Pasqua, et al.
Published: (2024-04-01)

Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination
by: Thomas E. Lew, et al.
Published: (2022-06-01)

Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia
by: Joel Brothers, et al.
Published: (2023-12-01)

Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
by: Lin Liu, et al.
Published: (2024-06-01)

Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature
by: Nil Albiol, et al.
Published: (2021-06-01)

Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia
by: Valerio Guarente, et al.
Published: (2021-09-01)

High <i>BECN1</i> Expression Negatively Correlates with <i>BCL2</i> Expression and Predicts Better Prognosis in Diffuse Large B-Cell Lymphoma: Role of Autophagy
by: Amreen Salwa, et al.
Published: (2023-07-01)

Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia
by: Juan Li, et al.
Published: (2025-12-01)

Preclinical assessment of combined BCL-2 and MCL-1 inhibition in high-risk neuroblastoma
by: Lindy Vernooij, et al.
Published: (2024-06-01)

Case Report: A Case of Epstein-Barr Virus-Associated Acute Liver Failure Requiring Hematopoietic Cell Transplantation After Emergent Liver Transplantation
by: Koji Nakajima, et al.
Published: (2022-01-01)

Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion
by: Diana Malarikova, et al.
Published: (2024-03-01)

BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia
by: Wing Fai Li, et al.
Published: (2024-11-01)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
by: Rie Nishi, et al.
Published: (2020-10-01)

Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations
by: Jie Yang, et al.
Published: (2025-09-01)

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
by: Xiang Zhang, et al.
Published: (2021-05-01)

BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies
by: Mariam Markouli, et al.
Published: (2025-01-01)

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
by: Petra Bašová, et al.
Published: (2025-01-01)

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
by: Anna Ferrari, et al.
Published: (2023-05-01)

The potential role of BCL-2 inhibition in amyloidosis and plasma cell leukemia
by: Grigorios Alvanidis, et al.
Published: (2025-03-01)

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report
by: Reilly Fankhauser, et al.
Published: (2024-11-01)